The bottom line as I see it is that the FDA granted Resverlogix Breakthrough Therapy Designation because of the very safe and promising data brought about by BOM. That data being that BOM confirmed a highly significant reduction in Death, Heart Attacks and Congestive Herat Failure. So what guarantee is there that if BOM2 produces the results found in BOM, (63% hazard reduction) will BP buy into Apabetalone. Do we know this for sure? We also have to keep in mind that these results were found in patients receiving SGLT2 or DPP4 inhibitors. Is this enough to take RVX stock as narmac would say "to the moon" eh!

Koo